Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR overexpressed colorectal cancer- supplementary dataset

Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib
(BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & methods:
Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light
scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared
spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used
to analyze nanoparticles. Results: According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited
HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential.
An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively.
Conclusion: Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.